Loading
A phase 3 trial of Daratumumab, Dexamethasone, Isatuximab in multiple myeloma, run by AstraZeneca, now recruiting.
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT is a phase 3 interventional study registered as NCT07764978 by AstraZeneca, with 750 participants planned, started 2026-06-26 and due to reach its primary completion in 2029-01-11. Interventions recorded: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide. Conditions listed: Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD0120, Daratumumab, Bortezomib, Dexamethasone.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares AZD0120, AstraZeneca, Multiple myeloma.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares Isatuximab, Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Isatuximab, Daratumumab, Bortezomib, Lenalidomide.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/